目的: 探索《国家基本医疗保险、工伤保险和生育保险药品目录》下限制性药品的多学科管理方法,建立规范诊疗审核中心管控医保限制性药品的药学干预模式。方法: 通过建立事前提醒和拦截干预、事中互动审核干预、事后处方（医嘱）点评和现场督导干预的全流程干预模式,对干预模式实施前（2020年1月1日 - 2021年12月31日）与实施后（2022年1月1日 - 2023年12月31日）的市医保局飞行检查涉及医保限制性药品违规金额、医保专项检查医保限制性药品支付合理率和疑似超限用药违规自查情况进行分析和对比。结果与结论: 规范诊疗审核中心干预模式实施后,市医保局飞行检查涉及医保限制性药品违规金额、医保专项检查医保限制性药品支付合理率和疑似超限用药违规情况明显改善。通过规范诊疗审核中心药学干预可有效促进药品的合理使用,助力医保限制性药品的管理。
Objective: To explore the multidisciplinary management method of restricted drugs under the national medical insurance catalog, and to establish a pharmaceutical intervention mode to control medical insurance restricted drugs by standardized diagnosis and treatment audit center. Methods: Through the establishment of the whole process intervention mode of pre reminder and interception intervention, in-process interactive audit intervention, post prescription (medical order) comment and on-site supervision intervention, the amount of delinquent medical insurance restricted drugs involved in the flight inspection of the municipal medical insurance bureau before the implementation of the intervention mode (January 1, 2020 ~December 31, 2021) and after the implementation (January 1st, 2022 - December 31st, 2023) were analyzed and compared, as well as the reasonable payment rate of medical insurance restricted drugs in the special inspection of medical insurance, and the self-examination of suspected exceed-indication drug use. Results and Conclusion: After the implementation of the intervention mode of the standardized diagnosis and treatment audit center, the amount of delinquent medical insurance restricted drugs involved in the flight inspection of the municipal medical insurance bureau, the reasonable payment rate of medical insurance restricted drugs in the special medical insurance inspection, and the suspected exceed-indication drug use were significantly improved. By the pharmaceutical intervention in the standardized diagnosis and treatment audit center, it effectively promoted the rational use of drugs and helped the management of medical insurance restricted drugs.
[1] 刘艳,田峰. 2019—2022版《医保药品目录》抗菌药物品种对比分析[J]. 中国处方药,2024,22(2):103-107.
[2] 姚华星,赵一丹. 2022版国家医保药品目录分类代码和限定支付条件分析[J]. 中国卫生标准管理,2024,15(5):6-10.
[3] 刘成刚. 浅谈我院医保控费与处方前置审核[J]. 兵团医学,2022,20(1):60-61.
[4] 杨燕,唐密,何江江. 医保药品目录调整视角下的卫生技术评估多维度决策框架研究[J]. 中国卫生经济,2023,42(11):28-32.
[5] 孟菲,李慧玲,李学林. 我院药品医保拒付情况及合理用药措施[J]. 中国医药导刊,2021,23(5):391-394.
[6] 马燕,申新田,朱晓倩. 医院处方点评制度下的医保药品合理应用研究[J]. 中国医院用药评价与分析,2021,21(8):1000-1002,1006.
[7] 韩兰萍,许霞青,刘凡凡,等. 基于处方前置审核系统拦截质子泵抑制剂注射剂超医保支付限制用药的成效分析[J]. 中国合理用药探索,2023,20(1):99-104.
[8] 张云玲,吴欣俐,蒋睿,等. 胸外科围手术期预防性使用质子泵抑制剂的药学干预效果分析[J]. 中国医院药学杂志,2022,42(9):921-925.
[9] 何行厉,谢林俊. 药师干预不合格处方对医保支出费用的影响及分析[J]. 中国卫生产业,2019, 16(35):15-17,20.
[10] 芦琳智,高亚玲,汪姗姗. 新形势下医保拒付费用原因及对策分析[J]. 中国医疗保险,2019(12):49-52.
[11] 陈治水,冷家骅,衡反修,等. 医疗机构信息辅助提示对医保拒付的影响探讨[J]. 中国医院管理,2017,37(4):50-52.
[12] 戴轶. 医院医疗保险费用拒付原因分析及解决办法[J]. 中国数字医学,2017,12(1):103-105.
[13] 刘猛,方可,何曼云,等. 全程药学干预模式应用于某院医保限制性药品的管理实践与成效评价[J]. 中国临床药学杂志,2024,33(4):255-259.
[14] 张夙,胡传文,葛琳,等. 处方前置审核防范医保拒付的实践与效果分析[J]. 医院管理论坛, 2021,38(7):19-22.
[15] 吴丽芳,林涛,蔡珊珊,等. 医保用药智能审核系统用于限定支付医保药品管控效果评价[J].中国药业,2023,32(12):6-9.
